Embla Medical hf
CSE:EMBLA

Watchlist Manager
Embla Medical hf Logo
Embla Medical hf
CSE:EMBLA
Watchlist
Price: 33.4 DKK -8.24% Market Closed
Market Cap: 14.4B DKK

Embla Medical hf
Investor Relations

Embla Medical hf, a rising star in the medical device industry, has carved a niche in the sleep diagnostics sector with its innovative technology. Founded with the vision of transforming sleep health, the Iceland-based company specializes in developing advanced sleep diagnostic systems. These devices are crucial in identifying sleep disorders, a growing concern globally as awareness about sleep health continues to rise. Embla Medical’s flagship products are portable and user-friendly diagnostic tools that allow both clinicians and patients to monitor sleep patterns in real-time. By focusing on cutting-edge technology and accuracy, the company has established itself as a trusted partner in medical facilities worldwide, enhancing its reputation and solidifying its market presence.

The business model of Embla Medical relies heavily on the research and development of its diagnostic systems, complemented by a strategic emphasis on customer service and support. The revenue stream is generated through the sale of these sophisticated devices to hospitals, sleep clinics, and directly to healthcare providers. Additionally, they offer ongoing maintenance services and software updates, providing a continuous source of income post-sale. By integrating software with hardware, they ensure that their equipment remains at the forefront of technological advancements in sleep diagnostics. This not only drives sales but also builds a loyal customer base that places high value on efficacy and ease of use. Embla Medical's focus on innovation and customer satisfaction positions them well to capitalize on the growing market for sleep healthcare solutions.

Show more
Loading
EMBLA
OMX Copenhagen 25
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Oct 21, 2025
AI Summary
Q3 2025

Revenue Growth: Sales reached $237 million in Q3, driven by 7% organic growth, with total reported growth of 11% (including FX and M&A).

Segment Outperformance: Prosthetics & Neuro Orthotics delivered double-digit organic growth (13%), especially strong in APAC and EMEA, while Bracing & Supports was flat and Patient Care grew just 1%.

Profitability: EBITDA margin held steady at 22%, and gross margin was 63%. Net profit increased by 17% due to strong operating performance.

Guidance Reiterated: Full-year guidance maintained at 5–6% organic growth and 20–21% EBITDA margin, assuming some tariff absorption.

Tariff Impact: U.S. tariffs cost close to $2 million in the quarter; management expects similar or slightly higher impact in Q4 and is monitoring possible further trade restrictions.

Strategic Moves: Closed majority investment in Streifeneder ortho.production and launched the Odyssey iQ bionic foot; Patient Care segment undergoing major integration and rebranding.

Key Financials
Revenue
$237 million
Prosthetics & Neuro Orthotics Organic Growth
13%
Bracing & Supports Sales Growth
0%
Patient Care Sales Growth
1%
EBITDA Margin
22%
Gross Margin
63%
CapEx
$8 million
Free Cash Flow
$38 million
Net Interest-Bearing Debt to EBITDA
2.5x
Shares Issued
2.8 million
Shares Bought Back
525,000 shares ($2.7 million)
Earnings Call Recording
Other Earnings Calls

Management

Mr. Sveinn Solvason
President & CEO
No Bio Available
Mr. Ossur Kristinsson
Founder
No Bio Available
Ms. Gudny Arna Sveinsdottir
Chief Financial Officer
No Bio Available
Mr. Lukas Marklin
Chief Operating Officer
No Bio Available
Edda Lara Luovigsdottir
Investor Relations Director
No Bio Available
Ms. Margret Lara Fridriksdottir
Executive Vice President of People, Strategy & Sustainability
No Bio Available

Contacts

Address
Reykjavik
Grjothals 5
Contacts